TGFB1 and neoplasm: TGFβ-neutralizing antibody treatment also decreased BMET tumor burden, as measured histologically by cytokeratin-positive tumor area, by 65% (p < 0.05) vs. combined control groups, although the trend comparing vehicle or IgG control groups individually to 1D11 did not reach statistical significance (Figure 8B).